Compugen

NEWS

Sep 20, 2018

Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration with Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial

Sep 07, 2018

Compugen Announces First Patient Dosed with COM701, a First-in-Class Cancer Immunotherapy Antibody, in Phase 1 Clinical Trial

ALL NEWS

DISCOVERY

Holon

Our optimized process for predictive discovery of novel drug targets

DEVELOPMENT

San Francisco

Discovery & development of first-in-class monoclonal antibody therapeutics

Compugen, FROM CODE TO CURE

Our Pipeline

COM701/PVRIG (CGEN-15029)

CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...

COM902/TIGIT (CGEN-15137)

CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...

CGEN-15001T

CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...

CGEN-15001

CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...

Aug 01, 2018

Compugen Second Quarter 2018 Conference Call (note 8:30 AM ET start time)

Holon, Israel

May 09, 2018

Compugen First Quarter 2018 Earnings Conference Call

Holon, Israel

Apr 02, 2018

MedImmune License Agreement

Holon, Israel

MORE EVENTS

Collaborations

In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...

In March 2018, Compugen entered into an exclusive license agreement with MedImmune, the global biologics research and ...

Click here for more info about partnering with Compugen